Abbott Laboratories (ABT)

Now's the time to load up on these high-yielders.

Analysts remain relatively more upbeat, but this could prove fleeting.

Visa, Home Depot, and Abbott Laboratories are blue chip stocks that can provide your portfolio with a good mix of safety, stability, and dividend income over the long term.

Declining sales of plant-based meats have the company looking for other revenue sources.

Grail is on a quest to win in a $50 billion market.

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

This particular sector may suit cautious and aggressive investors.

Don't wait too long to buy the dip on these stocks.

These stocks are built for the long haul. And they pay great dividends.

This big pharma stock checks off a lot of boxes.

They have increased their payouts for a combined 171 years straight.

See the recent insider activity surrounding Okta, Micron Technology, and Abbott Laboratories, and what these moves signal to investors.

The Schwab U.S. Dividend Equity ETF checks off all the key boxes investors are likely going to want from a top dividend investment.

Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.

This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.

Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.

They have combined for 118 years of consecutive dividend increases.

These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.

These stocks check off multiple boxes for income investors.

A rare yield, Dividend King status, and a steady healthcare business may be creating one of its most interesting income setups in years.

This company, which has raised its dividend for 54 consecutive years, is on sale.